A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older
Latest Information Update: 26 May 2023
Price :
$35 *
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 22 May 2023 Status changed from active, no longer recruiting to completed.
- 01 Dec 2021 Results published in The Lancet Infectious Diseases
- 03 Dec 2020 Status changed from recruiting to active, no longer recruiting.